Assessment of quality of life measured by rhinoconjuctivits quality of life questionnaire in patients of allergic rhinitis treated with commonly used oral antihistaminics


  • Ganesh S. Pentewar Department of Pharmacology, MIMER Medical College, Talegaon Dabhade, Maharashtra, India
  • Ranjit J. Wagh Department of Pharmacology, MIMER Medical College, Talegaon Dabhade, Maharashtra, India



Allergic rhinitis, Antihistaminic, Quality of life, RQLQ


Background: Nasal and non-nasal symptoms in allergic rhinitis (AR) can be assessed by measuring health related quality of life (HRQOL). Present study was to assess the impact of use of antihistaminic in AR which will affect the work productivity, sleep, frequent visits to health care professional and expenditure on medicines. For this evaluation, Rhinoconjuctivits Quality Of Life Questionnaire (RQLQ) has been used.

Methods: In this study 52 patients with AR were randomized in an open-label, 4-arm, parallel group, single center study. Questionnaire information was obtained about allergy-related RQLQ. Subjects received either Tablet Cetirizine 5 mg, Levocetirizine 5 mg, Loratidine 5 mg or Fexofenadine 120 mg. Changes from baseline until the end of study visit (1 week following) were evaluated by RQLQ.

Results: When compared between treatment groups using one-way ANOVA it was observed that there is no variation in RQLQ overall Score in all the four treatment groups and there is no difference from treatment to treatment. Overall RQLQ score was reduced maximum in Levocetirizine group. Individual symptoms of RQLQ that is sleep score, non-hay fever, practical problem, nasal symptom score, Eye symptom Score, activities Score, and emotion score were also improved in the Levocetirizine group.

Conclusions: Patients of all four study groups showed an improved perception of their HRQL according to the RQLQ. Significant improvements are reported in nasal symptoms, daily activities, sleep and psychological impact. Our results provide support for an AR and its impact on quality of life. Our recommendation stipulating that levocetirizine is superior to rest drug group for the treatment of AR with safety and tolerability.


Bousquet J, Bullinger M, Fayol C, Marquis P, Valentin B, Burtin B. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol. 1994;94(2):182-8.

Bousquet J, Knani J, Dhivert H, Richard AL, Chicoye AN, Ware Jr JE, et al. Quality of life in asthma. I. Internal consistency and validity of the SF-36 questionnaire. Am J Respir Crit Care Med. 1994 Feb;149(2):371-5.

McHorney CA, Tarlov AR. Individual-patient monitoring in clinical practice: are available health status surveys adequate?. Qual Life Res. 1995 Aug 1;4(4):293-307.

McHorney CA. Generic health measurement: past accomplishments and a measurement paradigm for the 21st century. Ann Intern Med. 1997 Oct 15;127(8_Part_2):743-50.

Juniper EF, Guyatt GH, Griffith LE, Ferrie PJ. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol. 1996 Oct 1;98(4):843-5.

Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immuno. 1999 Aug 1;104(2):364-9.

Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exper Allergy. 1991 Jan;21(1):77-83.

Juniper EF, Howland WC, Robertsa NB, Thompson AK, King DR. Measuring quality of life in children with rhinoconjunctivitis. J Allergy Clin Immunol. 1998 Feb 1;101(2):163-70.

Juniper EF, Guyatt GH, Dolovich J. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol. 1994 Feb 1;93(2):413-23.

Demoly P, Bousquet PJ, Mesbah K, Bousquet J, Devillier P. Visual analogue scale in patients treated for allergic rhinitis: an observational prospective study in primary care: asthma and rhinitis. Clin Exp Aller. 2013 Aug;43(8):881-8.

Canonica GW, Bousquet J, Van Hammée G, Bachert C, Durham SR, Klimek L, et al. Levocetirizine improves health-related quality of life and health status in persistent allergic rhinitis. Resp Med. 2006 Oct 1;100(10):1706-15.

Van Cauwenberge P, Juniper EF. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. ClinExp Allergy. 2000 Jun;30(6):891-9.

Segall N, Gawchik S, Georges G, Haeusler JM. Efficacy and safety of levocetirizine in improving symptoms and health-related quality of life in US adults with seasonal allergic rhinitis: a randomized, placebo-controlled study. Ann Allergy Asthma Immunol. 2010 Mar;104(3):259-67.

Bachert C, Bousquet J, Canonica GW, Durham SR, Klimek L, Mullol J, et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Aller Clin Immunol. 2004;114(4):838-844.

Rogkakou A, Villa E, Garelli V, Canonica GW. Persistent Allergic Rhinitis and the XPERT Study. World Allergy Organ J. 2011;4(3 Suppl):S32–S36.

Lee CF, Sun HL, Lu KH, Ku MS, Lue KH. The comparison of cetirizine, levocetirizine and placebo for the treatment of childhood perennial allergic rhinitis. Pediatr Aller Immunol. 2009 Aug;20(5):493-9.




How to Cite

Pentewar, G. S., & Wagh, R. J. (2019). Assessment of quality of life measured by rhinoconjuctivits quality of life questionnaire in patients of allergic rhinitis treated with commonly used oral antihistaminics. International Journal of Basic & Clinical Pharmacology, 8(8), 1830–1837.



Original Research Articles